COMT offers a service similar to that offered by Innovascreen Inc (Halifax, Canada - ASET -Avian System for Evaluation of Therapeutics) to test the invasive, pro-metastatic and pro-angiogenic potential of a given cell type or agent and assess the anti-neoplastic and/or anti-metastatic effect of lead biological or synthetic compounds exploited as therapeutics. The service is based upon the chick embryo chorioallantoic membrane assay (CAM assay) and intravital fluorescence microscopy supported by immunochemistry and molecular biological end-point analyses. For the performance of the assay it is possible to access the model tumour cell lines adopted by COMT, or provide proper primary or established cell lines to be tested. The assay allows to dissect the processes of intra- and extravasation of tumour cells and the process of neovessel formation qualitatively and quantitatively and in real-time, under the influence of agonists or antagonists.

References

Dr Domenica Mangieri, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it., Tel. (+39) 0521-906003

Dr Mirca Lazzaretti, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it., Tel. (+39) 0521-905608

Please request quotation